No defined molecular host target

No defined molecular host target is a terminology used within pharmacological databases such as ChEMBL to describe instances where a drug's therapeutic effect cannot be linked to a specific molecular entity like a protein or nucleic acid (ChEMBL, 2024). This often applies to agents that function through non-specific chemical or physical processes, such as antacids that neutralize gastric acid or osmotic laxatives that draw water into the intestinal lumen (IUPHAR/BPS Guide to Pharmacology, 2023). Historically, many drugs were discovered through phenotypic assays where the clinical benefit was observed without knowledge of the underlying molecular trigger, leading to their classification under this placeholder (Nature Reviews Drug Discovery, 2011). For drug developers, this designation indicates a lack of a clear structure-activity relationship driven by a single binding site, which can make traditional lead optimization challenging. While some drugs in this category may eventually have their targets identified through advanced proteomics, others will remain classified as non-specific due to their inherent mode of action. Consequently, safety and efficacy for these substances are typically monitored through systemic physiological responses rather than molecular biomarkers. This classification serves as a critical reminder of the limitations in our current understanding of the complete interactome for certain established therapies.

Other names

Unknown targetNon-specific mechanismUnidentified molecular targetNon-molecular target

Drugs associated with this classification typically act via non-mediated pathways such as chemical neutralization, osmotic pressure changes, or physical lubrication, rather than through high-affinity binding to a specific protein or genomic sequence (ChEMBL, 2024; IUPHAR/BPS Guide to Pharmacology, 2023).